Agamree
What Agamree is used for
Agamree is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Agamree
- Active substance
- vamorolone
- Disease area
- Muscular Dystrophy, Duchenne
- Medicine group
- Glucocorticoids
- ATC code
- H02AB18
- Marketing authorisation holder
- Santhera Pharmaceuticals (Deutschland) GmbH
- Authorised in the EU since
- 2023
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Agamree used for?
Agamree is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.
What is the active substance in Agamree?
Agamree contains vamorolone.
Who makes Agamree?
The EU marketing authorisation holder is Santhera Pharmaceuticals (Deutschland) GmbH.
Is Agamree an orphan medicine?
Yes. Agamree is designated an orphan medicine in the EU, for a rare disease (Muscular Dystrophy, Duchenne).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU